MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$13,544K
Net Income
-$40,552K
Net Profit Margin
-299.41%
EPS
-$2.44
Unit: Thousand (K) dollars
Revenue Breakdown
Tonmya
Zembrace Symtouch
Tosymra
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Product revenue, net
13,544
6,878
3,237*
3,290
Cost of sales
703
1,578
2,539*
1,367
Research and development
19,417
18,213
16,686*
9,289
Selling, general and administrative
35,959
28,624
10,581*
25,701
Total operating expenses
56,079
48,415
29,806*
36,357
Operating loss
-42,535
-41,537
-26,569*
-33,067
Grant income
600
0
66*
982
Loss on extinguishment of debt
-
0
-2,092*
0
Interest income
-
1,346
453*
1,231
Interest expense
-
-
22*
-
Interest income, net
1,432
-
-
-
Other expense, net
-49
-3
173*
-1,156
Net loss available to common stockholders
-40,552
-40,194
-27,991
-32,010
Basic EPS
-2.44
-2.93
-3.456
-3.59
Diluted EPS
-2.44
-2.93
-3.456
-3.59
Basic Average Shares
16,635,254
13,707,104
8,099,844
8,922,792
Diluted Average Shares
16,635,254
13,707,104
8,099,844
8,922,792
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss available
to common...
-$40,552K
Interest income, net
$1,432K
Grant income
$600K
Tonmya
$10,954K
Zembrace Symtouch
$1,996K
Tosymra
$594K
Operating loss
-$42,535K
Product revenue, net
$13,544K
Other expense, net
-$49K
Total operating
expenses
$56,079K
Selling, general and
administrative
$35,959K
Research and development
$19,417K
Cost of sales
$703K
Buy us a coffee
Tonix Pharmaceuticals Holding Corp. (TNXP)
Tonix Pharmaceuticals Holding Corp. (TNXP)